Plain-English translation of NCT05598528 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying people with advanced non-small cell lung cancer that has an EGFR gene mutation who are receiving one of three newer targeted medications — Osimertinib, Almonertinib, or Furmonertinib — as their first treatment. About 20% of patients don't respond well to these medications at first, and researchers want to understand why by studying blood samples, tumor samples, and imaging to identify which patients will benefit and which won't.
Even though this medication works very well for most people with this type of lung cancer, one in five patients see their cancer progress quickly anyway. Understanding the reasons behind this treatment resistance could help doctors predict who will respond and who might need a different approach from the start.
You likely qualify if…
You likely don't qualify if…
You will take one of the three targeted medications (your doctor will determine which one) as prescribed. Throughout your treatment, you will have regular clinic visits where doctors will monitor how well the medication is working using imaging scans and blood tests. You will also be asked to provide blood samples and possibly a tissue sample so researchers can study why some cancers resist the medication. The study involves standard cancer care visits plus additional research sample collection.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China